Loading...
Loading...
INFI| Name | Value |
|---|---|
| Revenues | 0.7M |
| Cost of Revenue | 0.4M |
| Gross Profit | 0.3M |
| Operating Expense | 11.8M |
| Operating I/L | -11.5M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.0M |
| Pretax | -11.0M |
| Income Tax Expense | -0.4M |
| Net Income/Loss | -10.6M |
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development of innovative cancer treatments. Its primary product candidate, IPI-549, is an orally administered immuno-oncology drug currently in Phase 2 clinical trials for metastatic triple negative breast cancer and urothelial cancer, as well as Phase 1/1b trials for solid tumors. The company generates revenue through strategic alliances and collaboration agreements with other pharmaceutical companies, such as Intellikine, Verastem, PellePharm, Arcus Biosciences, F. Hoffmann-La Roche, and Bristol Myers Squibb, to research, develop, and commercialize various pharmaceutical products targeting specific cancer-related enzymes and pathways.
